Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions

April 10, 2009
DOI: 10.4016/10761.01
4210 views
URL
Embed
Share

Please describe the reason for abuse:



Conference:
University of California, San Diego
Abstract:
The accumulating knowledge of human genomic variation is being used for the development of personalized medicine, with the aims of decreasing the number of adverse drug reactions and increasing the efficacy of drug treatment. Considerable pharmacogenomic research has focused on understanding the molecular mechanisms behind adverse drug reactions and finding biomarkers that identify people at risk. Serious adverse drug reactions have been shown to cause or contribute to 6 to 7% of all hospitalizations, a 2-day increase in the average length of hospitalization, and 100,000 deaths annually in the United States — and may, according to some estimates, cost about . . .
Description:
Dr. Magnus Ingelman-Sundberg presents his recent paper on "Pharmacogenomic biomarkers for prediction of "severe adverse drug reactions" published... » More